Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycerophosphoinositol (GPI) emollient ointment is a topical preparation used primarily for the management of atopic dermatitis and other dry, irritated skin conditions. It contains glycerophosphoinositol salt of choline as its main active ingredient. The mechanism of action involves moisturizing and softening the skin, reducing itching and flaking by forming an oily layer that traps water in the skin. In clinical studies, GPI emollient has demonstrated superior efficacy in reducing symptoms of atopic dermatitis compared to other commercially available emollients, with good safety and tolerance profiles[2][3]. Emollients like this are commonly used to restore the skin barrier function in dermatological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glycerophosphoinositol emollient ointment.